Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0525-2027

PuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL); Recall

PuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL);

FDA recall Class II

Open , Classified

FDA lists this Class II recall for PuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL);. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0525-2027
Recall classification
Class II
FDA database status
Open , Classified
Initiation date
Oct 9, 2026
FDA website posting date
Nov 20, 2026
Quantity in commerce
230
Distribution
See key details
FDA cause
Not reported

What is being recalled?

PuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL);

Affected model & UDI checker

Search the exact identifiers published for Z-0525-2027.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedPuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL);Check source notice00860007400315
Not specifiedPuraGel; Reference Code (Volume): 1. 651-004 (1 mL), 2. 651-005 (3 mL);Check source notice00860007400308
FDA code information

1. Reference Code (Volume): 1. 651-004 (1 mL); UDI-DI: 00860007400315; Lot numbers: 32525, 08223; 2. Reference Code (Volume): 651-005 (3 mL); UDI-DI: 00860007400308; Lot numbers: 05124, 28625;

View the original FDA recall notice

Why was this product recalled?

The instruction for use was missing additions FDA requested during the final interactive review of the premarket submission.

What actions did 3-D Matrix, Inc. take?

On October 9, 2026 CUSTOMER BULLETIN: PuraGel Oral Mucosa was emailed to customers. Actions to be taken: 1. Review this bulletin, along with the updated IFU, with all staff who use PuraGel and keep a copy with your inventory. 2. Do not use PuraGel for post-scaling or prophylaxis irritation and pain. 3. Use the application method and use conditions as described in this bulletin and in the updated eIFU on our website. 4. If you have used PuraGel outside the supported indications or in a patient with dry mouth and have a patient concern, or have seen any adverse event, contact us at (1-855-433-6633 ext. 4 / clinical@3dmatrix.com) Firm is planning on sending an URGENT: MEDICAL DEVICE RECALL: PURAGEL-Oral Mucosa letters were sent to customers. Actions to be taken: - Remove and replace all previous versions and delete electronic versions of the PuraGel IFU with the revised IFU. - Review the revised IFU attached to this bulletin or access at the following location below. - Review this bulletin, along with the updated IFU and other attachments, with all sta who use PuraGel and keep a copy with your inventory. - Use the revised IFU for future procedures. - Complete and return the attached Acknowledgement Form as soon as possible to USQuality@3DMatrix.com.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology